These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15789226)

  • 1. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
    Alexander RL; Greene BT; Torti SV; Kucera GL
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
    Lansakara-P DS; Rodriguez BL; Cui Z
    Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
    Wu W; Sigmond J; Peters GJ; Borch RF
    J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
    Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
    Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
    Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine.
    Cilurzo F; Cristiano MC; Da Pian M; Cianflone E; Quintieri L; Paolino D; Pasut G
    Anticancer Agents Med Chem; 2019; 19(12):1513-1522. PubMed ID: 31241440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
    Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.
    Peters GJ; Voorn DA; Kuiper CM; van der Wilt CL; Noordhuis P; Smid K; Myhren F; Sandvold M; Hendriks HR
    Nucleosides Nucleotides; 1999; 18(4-5):877-8. PubMed ID: 10432699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
    Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
    Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
    Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
    Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
    Bergman AM; Pinedo HM; Talianidis I; Veerman G; Loves WJ; van der Wilt CL; Peters GJ
    Br J Cancer; 2003 Jun; 88(12):1963-70. PubMed ID: 12799644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
    Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.